Tryp Therapeutics Inc. (TRYPF)
Tryp Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Kelowna, BC, CA. The stock last traded at $0.06, up 32.24% on the session, giving a market capitalisation of $5.4M. On trailing twelve-month figures it carries a trailing P/E of -1.46, a net margin of 0.0%. Its beta of -1.28 implies it has historically moved less than the broad market.
Tryp Therapeutics Inc. is a biopharmaceutical company dedicated to identifying and advancing novel therapeutic compounds for medical conditions characterized by significant unmet needs. Its flagship development initiative, known as PFN, focuses on addressing neuropsychiatric disorders by utilizing precisely formulated synthetic psilocybin. Within the PFN framework, specific drug candidates TRP-8802 and TRP-8803 are being developed to potentially treat a range of complex conditions, including fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. To support its research and clinical endeavors, the company collaborates with Calvert Labs for the conceptualization and execution of exploratory studies related to its psilocybin-based neuropsychiatric program. Additionally, a partnership with Fluence provides essential guidance and instruction for the psychotherapeutic components of Tryp's clinical trials. Established in 2019, the organization initially operated as Artos Pharma Corp. before rebranding as Tryp Therapeutics Inc. in June 2020. Its operations are headquartered in Kelowna, Canada.
Tryp Therapeutics Inc. is most often compared with the following Healthcare names: